Science & the Future · 1953 – today
Genetic Engineering for Busy People
From DNA to CRISPR to the Dire Wolf: What We Can Now Rewrite, and What Comes Next
The standard accounts were finished before the first approval in November 2023, and their own readers say the same three things: more about the scientists and their rivalries than they wanted to know, a first half that was very technical, and a future treated as an afterthought. Coverage applies the word cure to a therapy that most of the people who have the disease cannot reach, and the phrase designer babies to two different acts under two different sets of rules. The news moves faster than the maps.
This book is a briefing rather than a biography. Part One carries you from Mendel to the Human Genome Project in five short chapters. Part Two explains what an edit is and then reports the record as it stands: the therapy approved in London and Washington in 2023, the medicine for one child, the tomato on sale in Japan since 2021, the pigs, the wolves, and the edited babies. Part Three maps what comes next, from rare disease to gene drives, and names who decides. One habit runs through all of it: name the document a claim rests on, because an approval letter, a case report, a filing and a press release each prove something different.
Inside this book:
- How a bacterial defense became an aiming device, and why editing is a metaphor
- Casgevy: three weeks between two regulators, a $2.2 million list price, and the filing that counts who received it
- Six months from diagnosis to infusion for one boy, in the clinicians’ own careful words
- The dire wolf its own chief scientist called a gray wolf
- He Jiankui’s video, a three-year sentence for a crime that existed, and the law China wrote afterward
- Rare disease, aging, embryo screening, gene drives and four jurisdictions, with who decides named in each
Written for busy readers who meet this subject through headlines and podcasts, for families touched by a genetic condition who want the state of play stated plainly, and for anyone who stalled in a long CRISPR book. Ten words carry most of the science, each defined once, in layman’s terms; the futures are kept realistic and the ethics are mapped rather than preached.
The dates in this book will move. The habit of naming the document under a headline will not.
The book’s method
Name the Document
Every claim in this field reaches a reader through a document, and the kind of document decides what the claim can establish: a peer-reviewed paper, a regulator’s approval, a securities filing, a company announcement, a court ruling, a clause in a spending bill. Naming the document is the first and most useful thing anyone can do with a gene-editing headline.
Inside the book
- Introduction: The Medicine That Did Not Exist
- Part One: The Short Origin Story
- 01The Unit Nobody Could See
- 02The Shape and the Sentence
- 03Learning to Write
- 04Reading the Whole Book
- 05The Long Road Before CRISPR
- Part Two: Where the Science Stands
- 06Found, Not Invented
- 07What an Edit Actually Is
- 08Seven Months, One Prize, and a Patent War
- 09Base, Prime, and the Dimmer Switch
- 10The First Approved Cure
- 11A Medicine for One Boy
- 12Approval Is Not Access
- 13You Have Probably Already Eaten This
- 14The Pig That Grew a Kidney
- 15Three Wolves
- 16The Babies
- 17The Reboot
- 18Telling a Breakthrough From a Press Release
- Part Three: What Comes Next
- 19Seven Thousand Diseases
- 20When the Disease Is Common
- 21The Oldest Target
- 22The Argument About Children
- 23The Problem Nobody Owns
- 24The Box That Does Not Close
- 25Four Jurisdictions, Four Philosophies
- 26Who Decides
- Conclusion: What You Keep
Selected sources
A few of the documents and studies the book is built on.
- Mendel, G. (1866). Versuche über Pflanzen-Hybriden [Experiments on Plant Hybridization]. Verhandlungen des naturforschenden Vereines in Brünn, 4, 3-47. (Read at the sessions of 8 February and 8 March 1865.) Online ↗
- Watson, J. D., & Crick, F. H. C. (1953). A Structure for Deoxyribose Nucleic Acid. Nature, 171(4356), 737-738. Announced 25 April 1953. Nobel Prize in Physiology or Medicine 1962 (Crick, Watson, Wilkins). Online ↗
- Nirenberg, M. W., & Matthaei, J. H. (1961). The dependence of cell-free protein synthesis in E. coli upon naturally occurring or synthetic polyribonucleotides. PNAS, 47(10), 1588-1602. Nobel Prize in Physiology or Medicine 1968 (Holley, Khorana, Nirenberg). Online ↗
- Cohen, S. N., & Boyer, H. W. (1973). The first recombinant DNA organism (plasmid pSC101). Science History Institute biography. Online ↗
- Asilomar Conference on Recombinant DNA Molecules, February 1975; NIH guidelines, June 1976. FDA history of Humulin. Online ↗
- US Food and Drug Administration approval of recombinant human insulin (Humulin R), approval letter 28 October 1982; Eli Lilly with Genentech. Online ↗
- National Human Genome Research Institute (2003). International Consortium Completes Human Genome Project [press release, April 2003]; working draft published in Nature 409 and Science 291, February 2001. Online ↗
- Nurk, S., Koren, S., Rhie, A., Rautiainen, M., et al. (2022). The complete sequence of a human genome. Science, 376(6588), 44-53. Online ↗

